Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amikacin + ofloxacin is a combination of two antibiotics used primarily for the treatment of infections caused by resistant or atypical bacteria, including Mycobacterium fortuitum. Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to cell death. Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. This combination has been used in clinical settings for difficult-to-treat soft tissue and wound infections, particularly those following surgery or involving nontuberculous mycobacteria[1][2]. Both drugs exhibit strong bactericidal activity with prolonged postantibiotic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amikacin + ofloxacin.